Moreover, a synergistic effect on apoptosis was observed with the combination of IPAT and other antineoplastic agents, including taselisib, paclitaxel, and duligotuzumab, suggesting that inhibition of PI3K/AKT signaling by IPAT is able to enhance the apoptotic response of combination treatments as compared to monotherapy in cancer cells [28,36]. The gene discussed is PIK3CA; the disease is cancer.